The Tumor Profiler Study: integrated, multi-omic, functional tumor profiling for clinical decision support.
Journal
Cancer cell
ISSN: 1878-3686
Titre abrégé: Cancer Cell
Pays: United States
ID NLM: 101130617
Informations de publication
Date de publication:
08 03 2021
08 03 2021
Historique:
pubmed:
23
1
2021
medline:
29
9
2021
entrez:
22
1
2021
Statut:
ppublish
Résumé
The application and integration of molecular profiling technologies create novel opportunities for personalized medicine. Here, we introduce the Tumor Profiler Study, an observational trial combining a prospective diagnostic approach to assess the relevance of in-depth tumor profiling to support clinical decision-making with an exploratory approach to improve the biological understanding of the disease.
Identifiants
pubmed: 33482122
pii: S1535-6108(21)00048-9
doi: 10.1016/j.ccell.2021.01.004
pii:
doi:
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
288-293Investigateurs
Melike Ak
(M)
Faisal S Al-Quaddoomi
(FS)
Jonas Albinus
(J)
Ilaria Alborelli
(I)
Sonali Andani
(S)
Per-Olof Attinger
(PO)
Daniel Baumhoer
(D)
Beatrice Beck-Schimmer
(B)
Lara Bernasconi
(L)
Anne Bertolini
(A)
Natalia Chicherova
(N)
Maya D'Costa
(M)
Esther Danenberg
(E)
Natalie Davidson
(N)
Monica-Andreea Drăgan
(MA)
Martin Erkens
(M)
Katja Eschbach
(K)
André Fedier
(A)
Pedro Ferreira
(P)
Bruno Frey
(B)
Linda Grob
(L)
Detlef Günther
(D)
Martina Haberecker
(M)
Pirmin Haeuptle
(P)
Sylvia Herter
(S)
Rene Holtackers
(R)
Tamara Huesser
(T)
Tim M Jaeger
(TM)
Katharina Jahn
(K)
Alva R James
(AR)
Philip M Jermann
(PM)
André Kahles
(A)
Abdullah Kahraman
(A)
Werner Kuebler
(W)
Christian P Kunze
(CP)
Christian Kurzeder
(C)
Sebastian Lugert
(S)
Gerd Maass
(G)
Philipp Markolin
(P)
Julian M Metzler
(JM)
Simone Muenst
(S)
Riccardo Murri
(R)
Charlotte K Y Ng
(CKY)
Stefan Nicolet
(S)
Marta Nowak
(M)
Patrick G A Pedrioli
(PGA)
Salvatore Piscuoglio
(S)
Mathilde Ritter
(M)
Christian Rommel
(C)
María L Rosano-González
(ML)
Natascha Santacroce
(N)
Ramona Schlenker
(R)
Petra C Schwalie
(PC)
Severin Schwan
(S)
Tobias Schär
(T)
Gabriela Senti
(G)
Vipin T Sreedharan
(VT)
Stefan Stark
(S)
Tinu M Thomas
(TM)
Vinko Tosevski
(V)
Marina Tusup
(M)
Audrey Van Drogen
(A)
Marcus Vetter
(M)
Tatjana Vlajnic
(T)
Sandra Weber
(S)
Walter P Weber
(WP)
Michael Weller
(M)
Fabian Wendt
(F)
Norbert Wey
(N)
Mattheus H E Wildschut
(MHE)
Shuqing Yu
(S)
Johanna Ziegler
(J)
Marc Zimmermann
(M)
Martin Zoche
(M)
Gregor Zuend
(G)
Informations de copyright
Copyright © 2021. Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Declaration of Interests B.S. is scientific co-founder and shareholder of Allcyte GmbH. L.P. and G.G. are listed as inventor on patents related to the 4i technology (WO 2019/207004; WO 2020/008071). G.R., K.-V.L., and S.G.S. are listed on a patent application related to single-cell analyses (European Patent Application No. 20170724.7). H.M. is on advisory boards for Bayer, Astra Zeneca, Janssen, Roche, and Merck. R.D. reports intermittent, project-focused consulting and/or advisory relationships with Novartis, Merck Sharp & Dohme (MSD), Bristol Myers Squibb (BMS), Roche, Amgen, Takeda, Pierre Fabre, Sun Pharma, Sanofi, Catalym, Second Genome, Regeneron, and Alligator outside the submitted work. G.R. is cofounder and on the Scientific Advisory Board of Computomics GmbH. M.P.L. is a co-founder and shareholder of Oncobit AG and receives research funding from Novartis, Roche, and Molecular Partners. The Tumor Profiler study is jointly funded by a public-private partnership involving F. Hoffmann-La Roche Ltd., ETH Zurich, University of Zurich, University Hospital Zurich, and University Hospital Basel.